|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.100 USD | -0.94% |
|
+0.96% | +53.28% |
Company Valuation: Allogene Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,126 | 907.1 | 540.2 | 446.6 | 307.9 | 724.8 | - | - |
| Change | - | -57.34% | -40.45% | -17.32% | -31.06% | 135.42% | - | - |
| Enterprise Value (EV) 1 | 1,317 | 330.6 | 91.47 | 234.8 | 347 | 539.1 | 624 | 618.8 |
| Change | - | -74.89% | -72.33% | 156.69% | 47.8% | 55.35% | 15.75% | -0.83% |
| P/E | -7.89x | -2.71x | -1.54x | -1.61x | -1.57x | -2.99x | -2.8x | -3.05x |
| PBR | 2.32x | 1.36x | 1.06x | 1.07x | 1.07x | 1.87x | 1.21x | 1.58x |
| PEG | - | -0.1x | 0.16x | 0x | 0x | 0.2x | -0.41x | 0.38x |
| Capitalization / Revenue | 55.2x | 3,733x | 5,686x | 20,300x | - | 120,804x | 55.9x | 7.47x |
| EV / Revenue | 34.2x | 1,361x | 963x | 10,673x | - | 89,857x | 48.1x | 6.38x |
| EV / EBITDA | -5.37x | -1.03x | -0.29x | -0.96x | -1.76x | -2.71x | -2.65x | -2.28x |
| EV / EBIT | -5.15x | -0.99x | -0.28x | -0.91x | -1.66x | -2.52x | -2.57x | -2.65x |
| EV / FCF | -6.38x | -1.46x | -0.38x | -1.17x | -2.32x | -3.55x | -3.82x | -5.04x |
| FCF Yield | -15.7% | -68.3% | -262% | -85.6% | -43.1% | -28.2% | -26.2% | -19.8% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.89 | -2.32 | -2.09 | -1.32 | -0.87 | -0.7024 | -0.75 | -0.6896 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.49 | 0.243 | 0.095 | 0.022 | - | 0.006 | 12.97 | 97.02 |
| EBITDA 1 | -245.3 | -321.2 | -313.5 | -243.8 | -197 | -198.7 | -235.9 | -271.5 |
| EBIT 1 | -255.8 | -335.4 | -327.7 | -257.5 | -209.3 | -214 | -242.7 | -233.6 |
| Net income 1 | -257 | -332.6 | -327.3 | -257.6 | -190.9 | -196.6 | -227.1 | -218.3 |
| Net Debt 1 | -809.5 | -576.5 | -448.7 | -211.8 | 39.16 | -185.7 | -100.8 | -106 |
| Reference price 2 | 14.920 | 6.290 | 3.210 | 2.130 | 1.370 | 2.100 | 2.100 | 2.100 |
| Nbr of stocks (in thousands) | 142,516 | 144,210 | 168,277 | 209,672 | 224,730 | 345,155 | - | - |
| Announcement Date | 2/23/22 | 2/28/23 | 3/14/24 | 3/13/25 | 3/12/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.99x | 89856.69x | -2.71x | -.--% | 725M | |
| 34.14x | 8.68x | 26.92x | 0.05% | 56.98B | |
| 20.2x | 6.2x | 13.51x | 1.5% | 53.58B | |
| -44.73x | 14.86x | -43.31x | -.--% | 25.63B | |
| -18.5x | 4.48x | -7.85x | -.--% | 23.51B | |
| 24.36x | 4.79x | 12.56x | -.--% | 19.43B | |
| 25.29x | 4.92x | 16.02x | -.--% | 18.12B | |
| 49.34x | 20.07x | 51.69x | 0.11% | 16.46B | |
| -495.91x | 34.06x | -3797.57x | -.--% | 14.13B | |
| 17.96x | 5.22x | 12.19x | -.--% | 14.35B | |
| Average | -39.08x | 8,996.00x | -371.86x | 0.17% | 24.29B | |
| Weighted average by Cap. | -14.67x | 277.91x | -210.57x | 0.35% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ALLO Stock
- Valuation Allogene Therapeutics, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
